KCT0008286招募中Unknown
A Phase II study of induction PD-1 blockade (nivolumab) in patients with surgically complete resectable mismatch repair deficient endometrial cancer (NIVEC)
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- Female
入选标准
- •1. Explicit and voluntary consent to participation in the trial obtained by signing and dating a consent form that clearly and completely describes the purpose, potential risks, and other important issues related to the trial.
- •2. Sex: female
- •3. Age (at the time of informed consent): 20 years and older
- •4. Subjects with histologically-or cytologically-confirmed endometrial cancer or carcinosarcoma(Mixed
- •Mullerain Tumor)
- •5. Clinical stage: Stage I – IIIC2 and surgically completely resectable
- •6. No evidence of distant metastases
- •7. MMRd or MSI-H subtype (defined by either deficient/loss expression of mismatch repair (MMR) proteins MLH1, PMS2, MSH2, MSH6 or microsatellite instability-high (MSI-H) by polymerase chain reaction assay for 5 microsatellite markers)
- •8. ECOG Performance Status Score 0 or 1
- •9. Patients with a life expectancy of at least 3 months
- •10. Patients whose latest laboratory data meet the below criteria within 7 days before first dose. If the date of the laboratory tests at the time of enrollment is not within 7 days before the first dose of the investigational product, testing must be repeated within 7 days before the first dose of the investigational product, and these latest laboratory tests must meet the following criteria. Of note, laboratory data will not be valid if the patient has received a granulocyte colony-stimulating factor (GCSF) or blood transfusion within 14 days before testing.
- •White blood cells =2,000/mm3
- •and neutrophils =1,500/mm3
- •Platelets =100,000/mm3
- •Hemoglobin =9.0 g/dL
- •AST (GOT) and ALT (GPT) =3.0-fold the upper limit of normal (ULN) of the study site (or =5.0-
- •fold the ULN of the study site in patients with liver metastases)
- •Total bilirubin =1.5-fold the ULN of the study site
- •Creatinine =1.5-fold the ULN of the study site or creatinine clearance (either the measured or
- •estimated value using the Cockcroft-Gault equation) >45 mL/min
- •11. Women of childbearing potential (including women with chemical menopause or no menstruation for
- •other medical reasons)#1 must agree to use contraception#2 from the time of informed consent until 5
- •months or more after the last dose of the investigational product. Also, women must agree not to
- •breastfeed from the time of informed consent until 5 months or more after the last dose of the
- •investigational product.
- •#1. Women of childbearing potential are defined as all women after the onset of menstruation who are
- •not postmenopausal and have not been surgically sterilized (e.g., hysterectomy, bilateral tubal ligation,
- •bilateral oophorectomy). Post-menopause is defined as amenorrhea for =12 consecutive months
- •without specific reasons. Women using oral contraceptives, intrauterine devices, or mechanical
- •contraception such as contraceptive barriers are regarded as having childbearing potential.
- •#2. The subject must consent to use any one of the following methods of contraception: a condom for
- •the subject’s partner (male), an intrauterine device (IUD) for female subjects, or skin implantation of a
- •rod contraceptive (Implanon).
- •#3. Complete sexual abstinence is also acceptable: Sexual abstinence is considered highly effective
- •only if it is defined as abstaining from sexual intercourse with the opposite sex for the entire duration
- •of the trial treatment-related risks. The reliability of sexual abstinence in relation to the duration of the
- •trial needs to be evaluated, and sexual abstinence should be a preferred and rout
排除标准
- •1. Patients with multiple primary cancers (with the exception of completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, intramucosal carcinoma, or superficial bladder cancer, or any other cancer that has not recurred for at least 5 years)
- •2. Patients with residual adverse effects of prior therapy or effects of surgery that would affect the safety evaluation of the investigational product in the opinion of the investigator or sub-investigator.
- •3. Patients with current or past history of severe hypersensitivity to any other antibody products
- •4. Patients with concurrent autoimmune disease or history of chronic or recurrent autoimmune disease
- •5. Patients with a current or past history of interstitial lung disease or pulmonary fibrosis diagnosed based on imaging or clinical findings. Patients with radiation pneumonitis may be randomized if the radiation pneumonitis has been confirmed as stable (beyond acute phase) without any concerns about recurrence.
- •6. Patients with concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease
- •7. Patients with pericardial fluid, pleural effusion, or ascites requiring treatment
- •8. Patients with uncontrollable, tumor-related pain
- •9. Patients who have experienced a transient ischemic attack, cerebrovascular accident, thrombosis, or thromboembolism (pulmonary arterial embolism or deep vein thrombosis) within 180 days before randomization
- •10. Patients with a history of uncontrollable or significant cardiovascular disease meeting any of the following criteria:
- •? Myocardial infarction within 180 days before randomization
- •? Uncontrollable angina pectoris within 180 days before randomization
- •? New York Heart Association (NYHA) Class III or IV congestive heart failure
- •? Uncontrollable hypertension despite appropriate treatment (e.g., systolic blood pressure =150 mmHg or diastolic blood pressure = 90 mmHg lasting 24 hours or more)
- •? Arrhythmia requiring treatment
- •11. Patients receiving or requiring anticoagulant therapy for a disease. Patients receiving antiplatelet therapy including low-dose aspirin may be enrolled.
- •12. Patients with uncontrollable diabetes mellitus
- •13. Patients with systemic infections requiring treatment
- •14. Patients who have received systemic corticosteroids (except for temporary use, e.g., for examination or prophylaxis of allergic reactions) or immunosuppressants within 28 days before randomization
- •15. Patients who have received antineoplastic drugs (e.g., chemotherapy agents, molecular-targeted therapy agents, or immunotherapy agents) within 28 days before randomization
- •16. Patients who have undergone surgical adhesion of the pleura or pericardium within 28 days before randomization
- •17. Patients who underwent major surgery within 4 weeks or minor surgery within 7 days prior to administration of the first investigational drug. Subjects should have adequately recovered from toxicity or complications from the intervention prior to initiation of study drug administration. Subjects planning major surgery during the treatment period should be excluded from the study (however, 2 weeks for video-assisted thoracoscopic surgery (VATS) or open-and-closed (ONC) surgery).
- •Note) Dilation and curettage under general anesthesia for diagnostic purposes is not applicable to the above, and the subject can be enrolled when the investigator judged that the patient has adequately recovered from the complications caused by the intervention.
研究者
相似试验
招募中
2 期
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)Endometrial NeoplasmsEndometrial CancerNCT05795244Yonsei University30
进行中（未招募）
2 期
PD-1 Antibody Therapy + Infliximab for Metastatic MelanomaMetastatic MelanomaNCT05034536Massachusetts General Hospital36
尚未招募
不适用
Randomized Phase II trial of a PD-1 inhibitor INCMGA00012 as consolidation therapy after definitive concurrent chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma (RHAPSODY)KCT0004857Asan Medical Center110
进行中（未招募）
1 期
Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLCmetastatic non-squamous Non-Small Cell Lung Cancer (Lung adenocarcinoma metastatic and Large cell lung cancer metastatic)MedDRA version: 21.1Level: PTClassification code 10069730Term: Large cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10064049Term: Lung adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005741-31-DEAIO-Studien-gGmbH130
尚未招募
2 期
Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically RemovedBreast CancerNCT06547476Guangdong Provincial People's Hospital40